Disease phenotype affects treatment of late-onset inflammatory bowel disease: Analysis of a large UK cohort
Inflammatory Bowel Diseases · 2026
DOI: 10.1093/ibd/izag072 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Peter F G Foulser und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolism, Digestion and Reproduction, Imperial College London, W2 1NY, London, United Kingdom. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Health Research Imperial Biomedical Research Centre based at Imperial College London and Imperial College Healthcare NHS Trust, Medical Research Council Clinician Scientist Fellowship, National Institute of Health Research Imperial Biomedical Research Centre.
Abstract (Originalsprache)
Background
The incidence of inflammatory bowel disease (IBD) in older adults is rising. Studies of late-onset (LO) (diagnosis ≥60 years of age) IBD are contradictory, with some suggesting increased use of corticosteroid and reduced use of advanced therapies. This multicenter study assessed disease phenotype and therapeutic choice in LO-IBD.
Methods
Patients recruited to the NIHR IBD BioResource with LO ulcerative colitis (UC) or Crohn’s disease (CD) were compared with those with young-onset (YO) (16-39 years of age) and mid-onset (MO) (40-59 years of age) IBD. Medication use and surgeries were assessed in propensity score–matched cohorts.
Results
A total of 32 012 patients were studied: 16 930 UC (2247 LO) and 15 082 CD (1409 LO). LO-UC was mostly left-sided, with less isolated proctitis. LO-CD patients had less ileocolonic and perianal disease. Corticosteroid, immunomodulator, and anti-tumor necrosis factor α (anti-TNF) use was lower in LO-UC and LO-CD; however, there was no difference in time to colectomy (LO-UC) or intestinal resection (LO-CD) compared with younger patients. LO-CD patients were more likely to receive vedolizumab and ustekinumab than YO-CD (odds ratio, 0.34 [95% confidence interval, 0.18-0.61] and 0.29 [95% confidence interval, 0.09-0.76], respectively). LO patients with perianal CD were less likely to receive anti-tumor necrosis factor or undergo perianal surgery than YO and MO patients with perianal CD (all P < .01).
Conclusions
LO-IBD has a distinct phenotype, with less isolated proctitis (LO-UC) and less ileocolonic and perianal CD. LO-IBD patients had lower corticosteroid, immunomodulator, and anti-tumor necrosis factor use but equivalent colectomy and intestinal resection rates. LO-CD is notable for the higher use of vedolizumab and ustekinumab, suggesting that age, comorbidity, and disease phenotype affect biologic choice in older adults. Research to understand whether differential treatment of older adults is justified is crucial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Metabolism, Digestion and Reproduction, Imperial College London, W2 1NY, London, United Kingdom.
- Department of Gastroenterology and Hepatology, Imperial College Healthcare NHS Trust, London, W2 1NY, United Kingdom.
- Department of Gastroenterology, London North West University Healthcare Trust, London, HA1 3UJ, United Kingdom.
- Department of Medicine, University of Cambridge, Cambridge, CB2 0AW, United Kingdom.
- Department of Gastroenterology, Cambridge University Hospitals NHS Trust, Cambridge, CB2 0QQ, United Kingdom.
ORCID-Profile: Peter F G Foulser, Laura Martinez-Gili, Sharmili Balarajah, James L Alexander, Benjamin H Mullish, Julian R Marchesi, Timothy R Orchard, Lucy C Hicks, Horace R T Williams
Förderung
- National Institute of Health Research Imperial Biomedical Research Centre based at Imperial College London and Imperial College Healthcare NHS Trust
- Medical Research Council Clinician Scientist Fellowship
- National Institute of Health Research Imperial Biomedical Research Centre
Zitieren
APA
Foulser, P. F. G., Martinez-Gili, L., Balarajah, S., Sundramoorthi, R., Alexander, J. L., Mullish, B. H., Marchesi, J. R., Parkes, M., Orchard, T. R., Hicks, L. C., Williams, H. R. T., & UK IBD BioResource Investigators (2026). Disease phenotype affects treatment of late-onset inflammatory bowel disease: Analysis of a large UK cohort. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag072
Vancouver
Foulser PFG, Martinez-Gili L, Balarajah S, Sundramoorthi R, Alexander JL, Mullish BH, et al. Disease phenotype affects treatment of late-onset inflammatory bowel disease: Analysis of a large UK cohort. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag072
BibTeX
@article{Foulser2026,
author = {Foulser, Peter F G and Martinez-Gili, Laura and Balarajah, Sharmili and Sundramoorthi, Rohan and Alexander, James L and Mullish, Benjamin H and Marchesi, Julian R and Parkes, Miles and Orchard, Timothy R and Hicks, Lucy C and Williams, Horace R T and UK IBD BioResource Investigators, UK IBD BioResource Investigators},
title = {Disease phenotype affects treatment of late-onset inflammatory bowel disease: Analysis of a large UK cohort},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izag072}
}
EUVIMED